PPP1R21

Across TCGA pan-cancer cohorts, PPP1R21 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PPP1R21 data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PPP1R21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP1R21 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, BRCA, and UCEC are the cancer types where PPP1R21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	IV	0.036	0.602	<.001	42	view →
BRCA	OS	Median	All	0.335	0.924	.001	36	view →
UCEC	DFS	Median	All	1.000	0.608	.002	32	view →
LIHC	OS	Median	All	0.094	0.783	<.001	24	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	18	view →
BLCA	OS	Median	All	0.187	0.720	.006	9	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →
LGG	DFS	Median	All	0.249	0.728	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PPP1R21–MESO (OS)

Open the MESO breakdown →